Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate
The Maryland-based late-stage biotechnology company in April said it identified the candidate, NVX-CoV2373, with which it planned to use its Matrix-M adjuvant to enhance immune responses.
Latest News from Moneycontrol.com